20/07/2022 - General information
The IMIM-Hospital del Mar has been awarded three grants in the latest call. They are aimed at promoting the hiring of researchers with a doctoral degree at Spanish research centres. Three researchers from IMIM-Hospital del Mar have been selected in the latest call for the Juan de la Cierva-incorporation grants from the State Research Agency. The successful candidates are Joan Jiménez Balado, from the Neurovascular Research Group, Ana Rocío Conde Moro, from the Cellular Mechanisms in Physiological and Pathological Behaviour Research Group, and Helena Garcia Mieres, from the Health Services Research Group.
14/07/2022 - General information
After the success of "La mare de la ciència", the PRBB's science outreach podcast in Catalan, June saw the launch of "Absolutos y Relativos", the second science outreach podcast from the PRBB, which this time will be in Spanish. On 14 July, Patricia Robledo, a researcher from the Integrated Pharmacology and Systems Neuroscience research group at the IMIM, explains the neuroscience and drug studies she is carrying out, and talks about her research career, which is closely linked to psychology.
12/07/2022 - General information
This is one of the fifteen biomedical projects selected in the CaixaResearch Validate call. In this case, the study led by the researcher from the Hospital del Mar Medical Research Institute seeks effective immunotherapy treatment for breast tumours. The "la Caixa" Foundation is supporting 15 leading biomedical research projects in Spain and Portugal in the CaixaResearch Validate 2022 call. These are early-stage projects that the organisation wants to support to accelerate their arrival on the market, thereby helping them reach patients who may need them. Among those selected is a project led by Dr. Toni Celià-Terrassa, who heads up the Cancer Stem Cells and Metastasis Dynamics laboratory at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar).
28/06/2022 - General information
This is a study on the impact of the COVID-19 pandemic on the breast cancer screening program. Its main author is Dr. Guillem Bosch, resident physician of the PSMAR-UPF-ASPB Teaching Unit and member of the Health Services Research Group of the Hospital del Mar Medical Research Institute.
14/06/2022 - General information
It is published by Triacastela Publishing House. In it, Dr. Porta explains, in an easy and entertaining way, current epidemiological and public health issues, such as the management by governments of the COVID-19 pandemic. Epidemiology and epidemiologists have been in vogue over the last two years, when SARS-CoV-2 and COVID-19 have made all the headlines. A medical and scientific discipline that studies and acts on populations and groups of people under real conditions, which is carried out outside laboratories.
Més informació "Epidemiología cercana, the new book by Dr. Miquel Porta"
13/05/2022 - General information
A platform developed by the Centre Nacional d'Anàlisi Genòmica (CNAG-CRG) allows doctors and researchers from Catalan hospitals to share data and otherwise scattered expertise and diagnose patients with neurologic rare diseases. During the pilot project, a diagnosis was provided to 67 out of 323 patients (20.7% of cases), just by reanalysing previously available data. The results constitute an important milestone for ending the 'diagnostic odyssey' faced by patients in Catalonia. The collaborative approach also resulted in the identification of six new genes linked to specific diseases, which will make it easier to diagnose certain diseases in the future. The results, published today in The Journal of Molecular Diagnostics, were possible thanks to the Undiagnosed Rare Disease Program of Catalonia (URD-Cat), funded by the Departament de Salut de la Generalitat de Catalunya. The URD-Cat project was coordinated by the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) and involved more than 140 professionals from 15 different research centres and hospitals.
Més informació "Catalan collaboration helps end ‘diagnostic odyssey’ for rare disease patients"
21/04/2022 - General information
The research project PROMES-U has been launched with the goal of enhancing the mental health of university students through the exploration of factors influencing the onset of mental health issues. Additionally, the project aims to implement and evaluate online interventions for promoting mental well-being and preventing problems related to depression and anxiety. The study is led by the Hospital del Mar Medical Research Institute (IMIM) and involves participation from UPF, the University of the Balearic Islands, Jaume I University of Castellón, Miguel Hernández University of Elche, and the University of Zaragoza.
Més informació "PROMES-U Study Initiated to Promote Student Mental Health"
19/04/2022 - General information
The VALAWAI project, led by the CSIC with the participation of the Hospital del Mar Medical Research Institute and the Hospital del Mar, has received nearly four million euros from the European Innovation Council under the Pathfinder Challenges. A team from the Neuroimaging of Mental Disorders Research Group at the Hospital del Mar Medical Research Institute, led by Dr. Òscar Vilarroya, along with the Innovation Directorate of the Hospital del Mar, headed by Dr. Jordi Martínez, is part of the VALAWAI project (Value-Aware Artificial Intelligence). The project has recently been granted European funding of nearly four million euros. Its objective is to develop a set of tools for creating artificial intelligence systems that incorporate mechanisms sensitive to human values. In other words, these systems should be capable of deciding whether certain actions are morally acceptable and be aware of their users' value systems.
31/03/2022 - General information
The project "Tumour microenvironment-derived factors in localised colon cancer: clinical impact and therapeutic implications' (TuMiCC)"aimed at demonstrating the value of the tumour microenvironment in predicting relapse in patients with localised colon cancer treated with adjuvant therapy, has reached the 16-month development milestone, with patient recruitment and interesting advances in the molecular characterisation of this type of tumour and its environment.
30/03/2022 - General information
A study by the Neuroimmunology Research Group at the Hospital del Mar Medical Research Institute (IMIM) has validated a possible marker that could improve the efficiency of one of the main multiple sclerosis treatments. The marker is a specific type of immune system cell, known as NK (Natural Killer) cells, which express a specific receptor on their surface, NKG2C. Currently, patients with multiple sclerosis are treated with anti-CD20 monoclonal antibodies, which are designed to eliminate the B-lymphocyte population in peripheral blood and thus control disease activity. These drugs are scheduled to be administered once every six months, although it is unclear whether this time period is appropriate for all patients. Several studies indicate that, depending on the drug given, it takes between six months and a year and a half for the levels of the B-lymphocyte population to recover.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
